Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
30 participants
INTERVENTIONAL
2012-01-31
2013-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Blueberry Powder
Patients will take 30 grams of blueberry powder daily for up to 30 days.
Blueberry Powder
Patients will take 30 grams of blueberry powder daily for up to 30 days
Placebo Powder
Patients will take 30 grams of placebo powder daily for up to 30 days.
Placebo Powder
Patients will take 30 grams of placebo powder daily for up to 30 days.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blueberry Powder
Patients will take 30 grams of blueberry powder daily for up to 30 days
Placebo Powder
Patients will take 30 grams of placebo powder daily for up to 30 days.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Uric acid \> 6.0 mg/dL
Exclusion Criteria
* Currently receiving gout pharmacotherapy
* Current participation in another clinical trial
* Documented non-compliance or consistent missed appointments
* Women who are pregnant or nursing
18 Years
88 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
U.S. Highbush Blueberry Council
OTHER
University of Mississippi Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Daniel Riche
Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Daniel Riche, Pharm.D.
Role: PRINCIPAL_INVESTIGATOR
University of Mississippi Medical Center
Marion Wofford, M.D., M.P.H.
Role: PRINCIPAL_INVESTIGATOR
University of Mississippi Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Mississippi Medical Center
Jackson, Mississippi, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2011-0218
Identifier Type: -
Identifier Source: org_study_id